https://www.selleckchem.com/products/GDC-0449.html
Recently, hormonal therapy using abiraterone acetate, a second-generation androgen receptor axis-targeted agent, was reported to improve overall survival and progression-free survival in men with LATITUDE-high-risk metastatic castration-sensitive prostate cancer. This observational multicenter study aimed to assess the efficacy of upfront abiraterone acetate in Japanese patients with LATITUDE-high-risk metastatic castration-sensitive prostate cancer. The present study included 112 Japanese patients with LATITUDE-high-risk metastatic ca
Me gusta
Comentario
Compartir
